Journal article
Randomized phase 2 trial comparing JNJ‐9375, a thrombin‐directed antibody, with apixaban for prevention of venous thrombosis
Abstract
BACKGROUND: JNJ-9375 is an antibody against exosite 1 on thrombin, inhibits substrate binding but not catalytic activity.
OBJECTIVE: To examine the possibility that JNJ-9375 attenuates thrombosis without affecting hemostasis, we compared the efficacy and safety of JNJ-9375 and apixaban.
Authors
Weitz JI; Segers A; Raskob G; Roberts RS; Francis C; Lassen MR; Fuji T; Swaim RM; Lee M; Peters G
Journal
Journal of Thrombosis and Haemostasis, Vol. 17, No. 12, pp. 2081–2088
Publisher
Elsevier
Publication Date
December 2019
DOI
10.1111/jth.14639
ISSN
1538-7933
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAntibodies, Monoclonal, HumanizedAnticoagulantsArthroplasty, Replacement, KneeBlood CoagulationDouble-Blind MethodFactor Xa InhibitorsFemaleHemorrhageHumansInfusions, IntravenousMaleMiddle AgedPyrazolesPyridonesThrombinThrombin TimeTime FactorsTreatment OutcomeVenous ThromboembolismVenous Thrombosis